When you strip out the buzzwords, an RDT is a mediocre design that companies fall back on when they don’t know how to enrich a phase-2 trial with a biomarker.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”